Naltrexone Promotes Weight Loss in Women With Schizophrenia
the Psychiatry Advisor take:
Patients with schizophrenia are more likely to be overweight compared to the general population. Now, a drug that is normally used to ween people off of alcohol or narcotics has been shown to promote weight loss in those with schizophrenia.
Cenk Tenk, MD, director of the psychosis program at the Connecticut Mental Health Center in New Haven, and colleagues examined whether giving naltrexone (Revia, Vivitrol) to patients would lead to weight loss. In their study, 24 overweight women with a diagnosis of either schizophrenia or schizoaffective disorder were randomized the received naltrexone 25mg/day for 8 weeks or placebo.
Women with schizophrenia are at a particular risk for weight gain and related disorders, such as diabetes and cardiovascular disease, due to side effects of taking anti-psychotics. As a result, they are also at increased risk for morbidity and mortality.
Patients in the naltrexone group had significant weight loss (-3.40 kg) compared to weight gain (+1.37 kg) in the patients in the placebo group, the researchers reported in the Journal of Clinical Psychopharmacology. Mostly non-diabetics lost weight in the drug-treatment group.
“These data support the need to further investigate the role of D2 blockade in reducing food reward-based overeating,” the researchers concluded. “A larger study addressing the weaknesses of this pilot study is currently underway."
Naltrexone Promotes Weight Loss in Female Patients With Schizophrenia
Sign Up for Free e-newsletters
Psychiatry Advisor Articles
- Differences in Efficacy and Tolerability of ADHD Medications Across Age Groups
- Rapid Cycling Bipolar Disorder Associated With ADHD and Female Gender
- Associations Between Hypovitaminosis D and Poorer Outcomes in Schizophrenia
- Oxycontin's Maker Now Selling Drug to Curb Opioid Addiction
- Symptom Trajectories Vary According to Language Development in Autism
- Quetiapine Exposure Does Not Appear to Increase Risk for Infant Malformations
- Selective Serotonin Reuptake Inhibitors May Increase Risk for Suboptimal Fetal Growth
- Transdermal Nicotine Boosts Mood and Cognitive Function in Late-Life Depression
- Ketamine Infusions Reduce Suicidal Ideation in Depression: Characterizing Different Responses
- Prenatal Insecticide Exposure in Mother May Be Linked to Risk for Autism in Children